The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Cesare Gridelli

S.G. Moscati Hospital

Avellino

Italy

[email]@libero.it

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • S.G. Moscati Hospital, Avellino, Italy. 2012
  • Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy. 2003 - 2012
  • Oncologia Medica, Az. Sanitaria S. Giuseppe Moscati, Avellino, Contrada Amoretta-83100, Italy. 2010
  • UO Oncologia Medica, Azienda Ospedaliera S.G. Moscati, Avellino, Italy. 2004
  • Unità Operativa di Oncologia Medica, Azienda Ospedaliera S.G. Moscati, Via Circumvallazione 68, Avellino 83100, Italy. 2004
  • Clinical Trials Unit, National Cancer Institute, Via M Semmola, 80131 Naples, Italy. 2003

References

  1. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. Gridelli, C., Ciardiello, F., Gallo, C., Feld, R., Butts, C., Gebbia, V., Maione, P., Morgillo, F., Genestreti, G., Favaretto, A., Leighl, N., Wierzbicki, R., Cinieri, S., Alam, Y., Siena, S., Tortora, G., Felletti, R., Riccardi, F., Mancuso, G., Rossi, A., Cantile, F., Tsao, M.S., Saieg, M., da Cunha Santos, G., Piccirillo, M.C., Di Maio, M., Morabito, A., Perrone, F. J. Clin. Oncol. (2012) [Pubmed]
  2. Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer. Gridelli, C., Brodowicz, T., Langer, C.J., Peterson, P., Islam, M., Guba, S.C., Moore, P., Visseren-Grul, C.M., Scagliotti, G. Clin. Lung. Cancer (2012) [Pubmed]
  3. The Role of EGFR Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non Small Cell Lung Cancer Patients Harboring EGFR Mutation. Sgambato, A., Casaluce, F., Maione, P., Rossi, A., Rossi, E., Napolitano, A., Palazzolo, G., Bareschino, M.A., Schettino, C., Sacco, P.C., Ciadiello, F., Gridelli, C. Curr. Med. Chem. (2012) [Pubmed]
  4. Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trial. Gridelli, C., Gallo, C., Morabito, A., Iaffaioli, R.V., Favaretto, A., Isa, L., Barbera, S., Gamucci, T., Ceribelli, A., Filipazzi, V., Maione, P., Rossi, A., Barletta, E., Signoriello, S., De Maio, E., Piccirillo, M.C., Di Maio, M., Rocco, G., Vecchione, A., Perrone, F. J. Thorac. Oncol (2012) [Pubmed]
  5. Targeting Angiogenesis for Treatment of NSCLC Brain Metastases. Schettino, C., Bareschino, M.A., Rossi, A., Maione, P., Sacco, P.C., Colantuoni, G., Rossi, E., Gridelli, C. Curr. Cancer. Drug. Targets (2012) [Pubmed]
  6. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. Gridelli, C., De Marinis, F., Di Maio, M., Cortinovis, D., Cappuzzo, F., Mok, T. Lung. Cancer (2011) [Pubmed]
  7. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Gridelli, C., De Marinis, F., Di Maio, M., Cortinovis, D., Cappuzzo, F., Mok, T. Lung. Cancer (2011) [Pubmed]
  8. Pemetrexed in advanced non-small cell lung cancer. Gridelli, C., Maione, P., Rossi, A., Bareschino, M.A., Schettino, C., Sacco, P.C., Zeppa, R. Expert. Opin. Drug. Saf (2011) [Pubmed]
  9. Treatment, rationale, and study design of TALISMAN study: a randomized phase II open-label study of second-line erlotinib versus intermittent erlotinib dosing with docetaxel in the treatment of former-smoker men affected by recurrent squamous non-small-cell lung cancer. Gridelli, C., Rossi, A., Venturino, P., de Marinis, F. Clin. Lung. Cancer (2011) [Pubmed]
  10. The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer. Gridelli, C., Rossi, A., Bareschino, M.A., Schettino, C., Sacco, P.C., Maione, P. Expert. Opin. Investig. Drugs (2010) [Pubmed]
  11. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments. Gridelli, C., Maione, P., Bareschino, M.A., Schettino, C., Sacco, P.C., Ambrosio, R., Barbato, V., Falanga, M., Rossi, A. Anticancer Res. (2010) [Pubmed]
  12. Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Gridelli, C., Morabito, A., Gebbia, V., Mencoboni, M., Carrozza, F., Viganò, M.G., Verusio, C., Bollina, R., Mattioli, R., Valerio, M.R., Valmadre, G., Maione, P., Rossi, A., Cascone, T., Morgillo, F., Di Maio, M., Piccirillo, M.C., Gallo, C., Perrone, F., Ciardiello, F. Lung. Cancer (2010) [Pubmed]
  13. Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Gridelli, C., Ardizzoni, A., Douillard, J.Y., Hanna, N., Manegold, C., Perrone, F., Pirker, R., Rosell, R., Shepherd, F.A., De Petris, L., Di Maio, M., de Marinis, F. Lung. Cancer (2010) [Pubmed]
  14. Unanswered questions: monoclonal antibodies in the treatment of advanced non-small-cell lung cancer. Gridelli, C., Rossi, A. Oncology (Williston Park, N.Y.) (2010) [Pubmed]
  15. The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial. Gridelli, C., Di Maio, M. Expert. Opin. Pharmacother (2010) [Pubmed]
  16. Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy. Gridelli, C., Haiderali, A.M., Russo, M.W., Blackburn, L.M., Lykopoulos, K. Support. Care. Cancer (2010) [Pubmed]
  17. New avenues for second-line treatment of metastatic non-small-cell lung cancer. Gridelli, C., Maione, P., Rossi, A., Falanga, M., Bareschino, M., Schettino, C., Colantuoni, G., Guerriero, C., Nicolella, D., Rossi, E., Ferrara, M.L., Palazzolo, G. Expert. Rev. Anticancer. Ther (2009) [Pubmed]
  18. Management of unfit older patients with advanced NSCLC. Gridelli, C., Maione, P., Rossi, A., Palazzolo, G., Colantuoni, G., Rossi, E. Cancer Treat. Rev. (2009) [Pubmed]
  19. Treatment of advanced non-small-cell lung cancer in the elderly. Gridelli, C., Maione, P., Rossi, A., Ferrara, M.L., Castaldo, V., Palazzolo, G., Mazzeo, N. Lung. Cancer (2009) [Pubmed]
  20. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Gridelli, C., Rossi, A., Maione, P., Rossi, E., Castaldo, V., Sacco, P.C., Colantuoni, G. Oncologist (2009) [Pubmed]
  21. Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer. Gridelli, C., Maione, P., Ferrara, M.L., Rossi, A. Oncologist (2009) [Pubmed]
  22. Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line?. Gridelli, C., Maione, P., Rossi, A., Ferrara, M.L., Bareschino, M.A., Schettino, C., Sacco, P.C., Ciardiello, F. Oncologist (2009) [Pubmed]
  23. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Gridelli, C., Rossi, A., Maione, P., Ferrara, M.L., Castaldo, V., Sacco, P.C. Oncologist (2009) [Pubmed]
  24. The potential role of mTOR inhibitors in non-small cell lung cancer. Gridelli, C., Maione, P., Rossi, A. Oncologist (2008) [Pubmed]
  25. The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients. Gridelli, C., De Maio, E., Barbera, S., Sannicolo, M., Piazza, E., Piantedosi, F., Brancaccio, L., Morabito, A., Maione, P., Renda, F., Signoriello, G., Perrone, F. Lung. Cancer (2008) [Pubmed]
  26. An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial. Gridelli, C., Butts, C., Ciardiello, F., Feld, R., Gallo, C., Perrone, F. Clin. Lung. Cancer (2008) [Pubmed]
  27. Second-line treatment of advanced non-small cell lung cancer. Gridelli, C., Ardizzoni, A., Ciardiello, F., Hanna, N., Heymach, J.V., Perrone, F., Rosell, R., Shepherd, F.A., Thatcher, N., Vansteenkiste, J., De Petris, L., Di Maio, M., De Marinis, F. J. Thorac. Oncol (2008) [Pubmed]
  28. New insights in drug development for the non-small cell lung cancer therapy. Gridelli, C., Rossi, A., Maione, P., Ferrara, C., Del Gaizo, F., Guerriero, C., Nicolella, D., Palazzolo, G., Falanga, M., Colantuoni, G. Front. Biosci. (2008) [Pubmed]
  29. The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Gridelli, C., Rossi, A., Maione, P. Crit. Rev. Oncol. Hematol. (2008) [Pubmed]
  30. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting. Gridelli, C., Maione, P., Amoroso, D., Baldari, M., Bearz, A., Bettoli, V., Cammilluzzi, E., Crinò, L., De Marinis, F., Di Pietro, F.A., Grossi, F., Innocenzi, D., Micali, G., Piantedosi, F.V., Scartozzi, M. Crit. Rev. Oncol. Hematol. (2008) [Pubmed]
  31. Targeted therapy developments in the treatment of non-small cell lung cancer: a promising but long and winding road. Gridelli, C. Curr. Opin. Oncol (2008) [Pubmed]
  32. Erlotinib in non-small-cell lung cancer. Gridelli, C., Rossi, A., Maione, P., Colantuoni, G., Del Gaizo, F., Ferrara, C., Nicolella, D., Guerriero, C. Expert. Opin. Pharmacother (2007) [Pubmed]
  33. A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics. Gridelli, C., Rossi, A., Morgillo, F., Bareschino, M.A., Maione, P., Di Maio, M., Ciardiello, F. Clin. Lung. Cancer (2007) [Pubmed]
  34. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Gridelli, C., Maione, P., Del Gaizo, F., Colantuoni, G., Guerriero, C., Ferrara, C., Nicolella, D., Comunale, D., De Vita, A., Rossi, A. Oncologist (2007) [Pubmed]
  35. Erlotinib in non-small cell lung cancer treatment: current status and future development. Gridelli, C., Bareschino, M.A., Schettino, C., Rossi, A., Maione, P., Ciardiello, F. Oncologist (2007) [Pubmed]
  36. Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Gridelli, C., Gallo, C., Ceribelli, A., Gebbia, V., Gamucci, T., Ciardiello, F., Carozza, F., Favaretto, A., Daniele, B., Galetta, D., Barbera, S., Rosetti, F., Rossi, A., Maione, P., Cognetti, F., Testa, A., Di Maio, M., Morabito, A., Perrone, F. Lancet Oncol. (2007) [Pubmed]
  37. Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. Gridelli, C., Kaukel, E., Gregorc, V., Migliorino, M.R., Müller, T.R., Manegold, C., Favaretto, A., Martoni, A., Caffo, O., Schmittel, A., Rossi, A., Russo, F., Peterson, P., Muñoz, M., Reck, M. J. Thorac. Oncol (2007) [Pubmed]
  38. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. Gridelli, C., Maione, P., Illiano, A., Piantedosi, F.V., Favaretto, A., Bearz, A., Robbiati, S.F., Filipazzi, V., Lorusso, V., Carrozza, F., Iaffaioli, R.V., Manzione, L., Gallo, C., Morabito, A., Perrone, F. J. Clin. Oncol. (2007) [Pubmed]
  39. Lung cancer in the elderly. Gridelli, C., Langer, C., Maione, P., Rossi, A., Schild, S.E. J. Clin. Oncol. (2007) [Pubmed]
  40. A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics. Gridelli, C., Rossi, A., Mongillo, F., Bareschino, M., Maione, P., Ciardiello, F. Clin. Lung. Cancer (2007) [Pubmed]
  41. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments. Gridelli, C., Maione, P., Rossi, A., De Marinis, F. Oncologist (2007) [Pubmed]
  42. Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. Gridelli, C., Maione, P., Galetta, D., Colantuoni, G., Del Gaizo, F., Ferrara, C., Guerriero, C., Nicolella, D., Rossi, A. J. Thorac. Oncol (2007) [Pubmed]
  43. The use of bisphosphonates in elderly cancer patients. Gridelli, C. Oncologist (2007) [Pubmed]
  44. Adjuvant chemotherapy in elderly patients with non-small-cell lung cancer. Gridelli, C., Maione, P., Comunale, D., Rossi, A. Cancer. Control (2007) [Pubmed]
  45. Targeted therapies and non-small-cell lung cancer: new developments. Gridelli, C. Curr. Opin. Oncol (2007) [Pubmed]
  46. Does palliative chemotherapy beyond three courses benefit patients with non-small-cell lung cancer?. Gridelli, C. Nature Clinical Practice. Oncology (2007) [Pubmed]
  47. Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel. Gridelli, C., Aapro, M.S., Barni, S., Beretta, G.D., Colucci, G., Daniele, B., Del Mastro, L., Di Maio, M., De Petris, L., Perrone, F., Thatcher, N., De Marinis, F. Crit. Rev. Oncol. Hematol. (2007) [Pubmed]
  48. Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study. Gridelli, C., Ferrara, C., Guerriero, C., Palazzo, S., Grasso, G., Pavese, I., Satta, F., Bajetta, E., Cortinovis, D., Barbieri, F., Gebbia, V., Grossi, F., Novello, S., Baldini, E., Gasparini, G., Latino, W., Durante, E., Giustini, L., Negrini, C. J. Thorac. Oncol (2007) [Pubmed]
  49. Treatment of stage I-III non-small-cell lung cancer in the elderly. Gridelli, C., Maione, P., Rossi, A. Oncology (Williston Park, N.Y.) (2006) [Pubmed]
  50. Chemotherapy of advanced NSCLC in special patient population. Gridelli, C., Maione, P., Rossi, A., Guerriero, C., Ferrara, C., Del Gaizo, F., Colantuoni, G., Nicolella, D., Napolitano, L. Ann. Oncol. (2006) [Pubmed]
  51. New antiangiogenetic agents and non-small cell lung cancer. Gridelli, C., Rossi, A., Maione, P. Crit. Rev. Oncol. Hematol. (2006) [Pubmed]
  52. Treatment of locally advanced non-small cell lung cancer in the elderly. Gridelli, C., Maione, P., Rossi, A., Ciardiello, F., Raben, D. Curr. Opin. Oncol (2005) [Pubmed]
  53. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. Gridelli, C., Aapro, M., Ardizzoni, A., Balducci, L., De Marinis, F., Kelly, K., Le Chevalier, T., Manegold, C., Perrone, F., Rosell, R., Shepherd, F., De Petris, L., Di Maio, M., Langer, C. J. Clin. Oncol. (2005) [Pubmed]
  54. Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence. Gridelli, C., Shepherd, F.A. Chest (2005) [Pubmed]
  55. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Gridelli, C., Ardizzoni, A., Le Chevalier, T., Manegold, C., Perrone, F., Thatcher, N., van Zandwijk, N., Di Maio, M., Martelli, O., De Marinis, F. Ann. Oncol. (2004) [Pubmed]
  56. Factors influencing the choice of 5-HT3-receptor antagonist antiemetics: focus on elderly cancer patients. Gridelli, C., Aapro, M. Support. Care. Cancer (2004) [Pubmed]
  57. Gefitinib as salvage therapy in pretreated patients with advanced non-small cell lung cancer. Data from a compassionate use program. Gridelli, C., Rossi, A., Maione, P., Guerriero, C., Airoma, G., Colantuoni, G., Barzelloni, M.L. Anticancer Res. (2004) [Pubmed]
  58. Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly. Gridelli, C., Massarelli, E., Maione, P., Rossi, A., Herbst, R.S., Onn, A., Ciardiello, F. Cancer (2004) [Pubmed]
  59. Same old story? Do we need to modify our supportive care treatment of elderly cancer patients? Focus on antiemetics. Gridelli, C. Drugs. Aging (2004) [Pubmed]
  60. Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. Gridelli, C., Manegold, C., Mali, P., Reck, M., Portalone, L., Castelnau, O., Stahel, R., Betticher, D., Pless, M., Pons, J.T., Aubert, D., Burillon, J.P., Parlier, Y., De Marinis, F. Eur. J. Cancer (2004) [Pubmed]
  61. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Gridelli, C., Gallo, C., Di Maio, M., Barletta, E., Illiano, A., Maione, P., Salvagni, S., Piantedosi, F.V., Palazzolo, G., Caffo, O., Ceribelli, A., Falcone, A., Mazzanti, P., Brancaccio, L., Capuano, M.A., Isa, L., Barbera, S., Perrone, F. Br. J. Cancer (2004) [Pubmed]
  62. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. Gridelli, C., Perrone, F., Gallo, C., Cigolari, S., Rossi, A., Piantedosi, F., Barbera, S., Ferraù, F., Piazza, E., Rosetti, F., Clerici, M., Bertetto, O., Robbiati, S.F., Frontini, L., Sacco, C., Castiglione, F., Favaretto, A., Novello, S., Migliorino, M.R., Gasparini, G., Galetta, D., Iaffaioli, R.V., Gebbia, V. J. Natl. Cancer Inst. (2003) [Pubmed]
  63. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. Gridelli, C., Gallo, C., Shepherd, F.A., Illiano, A., Piantedosi, F., Robbiati, S.F., Manzione, L., Barbera, S., Frontini, L., Veltri, E., Findlay, B., Cigolari, S., Myers, R., Ianniello, G.P., Gebbia, V., Gasparini, G., Fava, S., Hirsh, V., Bezjak, A., Seymour, L., Perrone, F. J. Clin. Oncol. (2003) [Pubmed]
  64. 5-HT3-receptor antagonists in the control of delayed-onset emesis. Gridelli, C. Anticancer Res. (2003) [Pubmed]
  65. Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Gridelli, C., Rossi, A., Maione, P. Oncogene (2003) [Pubmed]
  66. Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer. Gridelli, C., Maione, P., Castaldo, V., Rossi, A. Br. J. Cancer (2003) [Pubmed]
 
WikiGenes - Universities